Literature DB >> 27652311

Co-activation of AMPK and mTORC1 as a new therapeutic option for acute myeloid leukemia.

Pierre Sujobert1, Jerome Tamburini1.   

Abstract

We report the therapeutic potential of GSK621, an AMP-activated protein kinase (AMPK) agonist, in acute myeloid leukemia (AML). GSK621-induced cytotoxicity is restricted to AML cells compared to normal hematopoietic progenitors due to a unique synthetic lethal interaction of co-activation of AMPK and mammalian target of rapamycin complex 1 (mTORC1) that involves the stress response pathway. AMPK activation thus represents an attractive perspective for cancer therapy.

Entities:  

Keywords:  AML; AMPK; GSK621; mTORC1; synthetic lethality

Year:  2015        PMID： 27652311      PMCID： PMC4972110          DOI： 10.1080/23723556.2015.1071303

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  10 in total

Review 1.  mTOR signaling in growth control and disease.

Authors:  Mathieu Laplante; David M Sabatini
Journal:  Cell       Date:  2012-04-13       Impact factor: 41.582

Review 2.  The concept of synthetic lethality in the context of anticancer therapy.

Authors:  William G Kaelin
Journal:  Nat Rev Cancer       Date:  2005-09       Impact factor: 60.716

3.  Co-activation of AMPK and mTORC1 Induces Cytotoxicity in Acute Myeloid Leukemia.

Authors:  Pierre Sujobert; Laury Poulain; Etienne Paubelle; Florence Zylbersztejn; Adrien Grenier; Mireille Lambert; Elizabeth C Townsend; Jean-Marie Brusq; Edwige Nicodeme; Justine Decrooqc; Ina Nepstad; Alexa S Green; Johanna Mondesir; Marie-Anne Hospital; Nathalie Jacque; Alexandra Christodoulou; Tiffany A Desouza; Olivier Hermine; Marc Foretz; Benoit Viollet; Catherine Lacombe; Patrick Mayeux; David M Weinstock; Ivan C Moura; Didier Bouscary; Jerome Tamburini
Journal:  Cell Rep       Date:  2015-05-21       Impact factor: 9.423

Review 4.  The PERKs of damage-associated molecular patterns mediating cancer immunogenicity: From sensor to the plasma membrane and beyond.

Authors:  A R van Vliet; S Martin; A D Garg; P Agostinis
Journal:  Semin Cancer Biol       Date:  2015-04-13       Impact factor: 15.707

5.  The LKB1-AMPK pathway-friend or foe in cancer?

Authors:  D Grahame Hardie
Journal:  Cancer Cell       Date:  2013-02-11       Impact factor: 31.743

6.  Antileukemic activity of rapamycin in acute myeloid leukemia.

Authors:  Christian Récher; Odile Beyne-Rauzy; Cécile Demur; Gaëtan Chicanne; Cédric Dos Santos; Véronique Mansat-De Mas; David Benzaquen; Guy Laurent; Françoise Huguet; Bernard Payrastre
Journal:  Blood       Date:  2004-11-18       Impact factor: 22.113

7.  The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation.

Authors:  Alexa S Green; Nicolas Chapuis; Thiago Trovati Maciel; Lise Willems; Mireille Lambert; Christophe Arnoult; Olivier Boyer; Valerie Bardet; Sophie Park; Marc Foretz; Benoit Viollet; Norbert Ifrah; François Dreyfus; Olivier Hermine; Ivan Cruz Moura; Catherine Lacombe; Patrick Mayeux; Didier Bouscary; Jerome Tamburini
Journal:  Blood       Date:  2010-07-28       Impact factor: 22.113

8.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

Authors:  Stephen M Ansell; Alexander M Lesokhin; Ivan Borrello; Ahmad Halwani; Emma C Scott; Martin Gutierrez; Stephen J Schuster; Michael M Millenson; Deepika Cattry; Gordon J Freeman; Scott J Rodig; Bjoern Chapuy; Azra H Ligon; Lili Zhu; Joseph F Grosso; Su Young Kim; John M Timmerman; Margaret A Shipp; Philippe Armand
Journal:  N Engl J Med       Date:  2014-12-06       Impact factor: 91.245

9.  Discrete mechanisms of mTOR and cell cycle regulation by AMPK agonists independent of AMPK.

Authors:  Xiaona Liu; Rishi Raj Chhipa; Shabnam Pooya; Matthew Wortman; Sara Yachyshin; Lionel M L Chow; Ashish Kumar; Xuan Zhou; Ying Sun; Brian Quinn; Christopher McPherson; Ronald E Warnick; Ady Kendler; Shailendra Giri; Jeroen Poels; Koenraad Norga; Benoit Viollet; Gregory A Grabowski; Biplab Dasgupta
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-13       Impact factor: 11.205

10.  Mitochondrial energetic and AKT status mediate metabolic effects and apoptosis of metformin in human leukemic cells.

Authors:  S Scotland; E Saland; N Skuli; F de Toni; H Boutzen; E Micklow; I Sénégas; R Peyraud; L Peyriga; F Théodoro; E Dumon; Y Martineau; G Danet-Desnoyers; F Bono; C Rocher; T Levade; S Manenti; C Junot; J-C Portais; N Alet; C Récher; M A Selak; M Carroll; J-E Sarry
Journal:  Leukemia       Date:  2013-04-09       Impact factor: 11.528
  10 in total
  2 in total

1.  Signalling mechanisms that regulate metabolic profile and autophagy of acute myeloid leukaemia cells.

Authors:  Olga Pereira; Alexandra Teixeira; Belém Sampaio-Marques; Isabel Castro; Henrique Girão; Paula Ludovico
Journal:  J Cell Mol Med       Date:  2018-08-17       Impact factor: 5.310

Review 2.  Targeting Metabolic Reprogramming in Acute Myeloid Leukemia.

Authors:  Isabel Castro; Belém Sampaio-Marques; Paula Ludovico
Journal:  Cells       Date:  2019-08-24       Impact factor: 6.600
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.